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ABSTRACT
Objective To assess clinical and radiological
performance of combined positron emission tomography/
computed tomography (PET/CT) in patients with secondary
and primary intraorbital tumours.
Methods 14 adults with secondary and 1 child with
primary orbital masses underwent combined whole-body
PET/CT. Radiopharmaceutical tracers applied were (18F)-
fluorodeoxyglucose, (18F)-fluoroethylcholine (FEC) and
(68Ga)-DOTATATE. Histopathology and/or all conventional
radiographic work-up and clinical course served as
standard of reference. Descriptive statistics and Fisher’s
exact test were used for analysis.
Results PET/CT detected all orbital masses. All 15
patients had malignant disease. Local osseous infiltration
was correctly identified in 11 patients. Lymph node
metastases were present in two of eight patients (25%)
with haematogenous orbital metastases and in five of six
patients (83%) with infiltrative carcinoma (p=0.05).
Further distant metastases were present in all eight
patients suffering from orbital metastases, but only one
patient with infiltrative carcinoma (17%) presented with
disseminated disease (p=0.003). In one metastasis, PET/
CT excluded vital orbital tumour tissue after radiation
therapy. Local recurrence was detected in another patient
suffering from prostate cancer.
Conclusion PET/CT is a sensitive tool for the detection
and localisation of orbital masses, enabling assessment of
both morphology and cell metabolism. Detailed imaging of
the head and neck region with a small field-of-view
should be performed when suspecting lymphatic
metastases. As metastatic disease to the orbit is associated
with advanced disease, focus should be laid on whole-
body imaging for staging of these patients. Different
radiopharmaceutical tracers can be applied to distinguish
the origin of orbital metastases.
INTRODUCTION
Incidence and conventional imaging of orbital
tumours
Orbital tumours account for approximately 0.1% of
all tumours and 18% of all orbital diseases.1
Contrast-enhanced CTand MRI can be considered as
the standard imaging techniques to evaluate orbital
tumours.2 Positron emission tomography (PET) with
(18F)-fluorodeoxyglucose (FDG) is a well-established
tool for staging and restaging of patients with cancer
of the mouth, pharynx and larynx3 and can be
applied for detecting residual tumour or recurrence
and for the identification of lymph node involve-
ment.4 Orbital metastases are rare in clinical practice5
and usually occur in disseminated disease.6 Nearly all
solid malignancies have been reported to metastasise
to the orbit, but the most frequent primary tumours
in adults spreading to the orbit are breast cancer
(42%), lung cancer (11%), cancer of unknown
primary (11%), prostate cancer (8.3%), cutaneous
melanoma (5.2%), cancer of the gastrointestinal tract
(4.4%) and kidney cancer (3.2%).1
Combined PET/CT imaging
In the past years, combined PET/CT imaging has
emerged as a diagnostic modality and its import-
ance has been proven in diagnosing and monitoring
patients with different malignancies (eg, lymphoma,
gastrointestinal tumours, non-small-cell lung
cancer, cutaneous melanoma, breast cancer).7–10
PET/CT successfully combines data on metabolic
activity obtained by PET with detailed morpho-
logical information gained from CT. Combined
application helps to minimise the limitations of
each modality by itself.7 11
Beyond (18F)-FDG, different other radiopharma-
ceutical tracers are available for PET/CT.
(68Ga)-DOTATATE (68-Ga-1,4,7,10-tetraazacyclo-
dodecane-N,N’,N’’,N’’’-tetraacetic acid-d-Phe(1),
Tyr(3)-octreotate), a selective somatostatin receptor
(SSTR) agonist,12 is applied for the detection of
meningioma or neuroendocrine tumours. For
imaging of other tumour entities that might metasta-
sise to the orbit, specific radiopharmaceutical tracers
such as, for example, (18F)-fluoroethylcholine
((18F)-FEC) or (68Ga)-PSMA (prostate-specific
membrane antigen) in prostate cancer are applied
regularly in clinical routine among others.13
PET/CT for the detection of orbital tumours
Since orbital tumours are rare disease entities, lit-
erature on the relevance of PET/CT for their detec-
tion to date is very limited. While PET/CT has
already been considered as a new method for diag-
nosing, staging, and restaging patients with orbital
lymphoma,14 the advantage in solid orbital
tumours is regarded controversial.15 Our study
group has reported on (68Ga)-DOTA-TATE PET/
CT as a useful tool in imaging orbital meningiomas
previously.12 The objective of the current study was
to evaluate the performance of the combined PET/




Selected patients were included retrospectively from
our PET/CT database. We searched our PET/CT
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database via the keywords ‘orbital tumors’ and ‘orbital pathology’.
As we wanted to evaluate PET/CT performance of solid malignant
tumours in this study, we then excluded all patients with orbital
lymphoma. We included all other patients consecutively (n=15).
This retrospective study has approval of the institutional
review board of the Department of Ophthalmology of Ludwig-
Maximilians-University of Munich/Germany. Written informed
consent had been obtained from each adult patient; in the child,
written informed consent had been obtained from parents,
respectively.
Indications for PET/CT scanning
Since orbital masses are quite rare, patients included formed a het-
erogeneous group of diagnoses for whole-body PET/CT scanning:
eight patients had metastatic cancer spreading to the orbit, six pre-
sented with tumours infiltrating into the orbit and one child pre-
sented with a primary orbital mass (for details see figure 1).
PET/CT acquisition and image analysis
PET/CT scanning was performed employing either a Philips
Gemini System (Philips Medical Systems, Hamburg, Germany)
or a Siemens Biograph TruePoint 64 (Siemens Medical
Solutions, Erlangen, Germany) or a GE Discovery 690 (GE
Healthcare, Munich, Germany). After fasting for 6 h, 20 mg
butylscopolamine (Buscopan; Boehringer Ingelheim, Ingelheim,
Germany), 20 mg furosemide and 250 MBq (range 217–
376 MBq) of the radiopharmaceutical tracer were applied intra-
venously in adults ((18F)-FDG in 11, (68Ga)-DOTA-TATE in 1
and (18F)-FEC in 2 patients). In the child 110MBq of
(18F)-FDG was administered. The imaging protocol included a
low-dose CT scan for attenuation correction of PET imaging
data acquired 60 min after intravenous administration of the
PET tracer, a whole-body PET scan obtained with multiple bed
positions, typically ranging from the top of the head to the
upper third of the thigh and a diagnostic contrast-enhanced
multidetector-row CT scan covering the range of the previous
PET scan. Using the Philips Gemini PET/CT, low-dose CT scan
settings were 20 mA, 140 kV and 512×512 matrix; PET data
were acquired with a field-of-view of 10 cm and 3 min per bed
position and the diagnostic CT scan was performed with 100–
190 mA, depending on the scanned region, 120 kV, collimation
2×5 mm and pitch 1.5, in the venous phase, 75 s after intraven-
ous injection of iodine-containing contrast agent (Ultravist 300;
Schering, Berlin, Germany) at a rate of 2.5 mL/s. Similar proto-
cols were applied with the other PET/CT scanners.
In one patient, due to known renal insufficiency, no contrast
agent was employed. Also in the child, CT was performed
without intravenous contrast agent. The reconstruction of the
PET data was performed in three dimensional mode, with and
without attenuation correction. CT data were evaluated alone,
after multiplanar reformatting (axial, coronal, sagittal), and as
combined PET/CT images as generated in with the Hermes
system (Hermes Medical Solutions, London, UK). Evaluation of
malignancy on CT was based on tumour morphology and pat-
terns of contrast enhancement. For lymph nodes, CT criteria of
malignancy included an axial diameter exceeding 10 mm and/or
nodal clustering (three or more lymph nodes adjacent to each
other), central necrosis and/or contrast enhancement. PET
images were evaluated for regions of focally increased glucose
uptake, typically with SUVmax exceeding a level of 5.
Validation of PET/CT findings
Histology served as standard of reference in 10 patients. The
remaining five patients had proven distant metastases from their
underlying disease making orbital metastasis most probable.
Whenever histopathology was not available, all previous and
subsequent imaging studies (MRI, PET/CT) along with the clin-
ical course and monitored treatment response served as standard
of reference (for details, please see table 1).
Statistical analysis
Statistical analysis was performed using SPSS (V.23.0) for
Windows (IBM; Armonk, New York, USA) employing Fisher’s
exact test and Microsoft Excel for Mac 2011.
RESULTS
Demographic data
Fifteen patients with orbital masses underwent whole-body
PET/CT scanning.
Adult patients’ median age was 70 years (range 46–79 years). We
also included one boy aged 7 years at the time of PET/CTexamin-
ation. Six patients had an orbital mass on the right eye, eight
patients on the left eye and one patient presented with bilateral
orbital infiltration. Eight patients were male and seven were female.
All orbital masses were detected by whole-body PET/CT (for
patient details, see table 1). Osseous infiltration was noted in 11
orbital tumours (five metastases, five infiltrative carcinomas and
one rhabdomyosarcoma).
PET/CT in rhabdomyosarcoma (n=1)
Patient number 9 suffered from histology-proven rhabdomyosar-
coma which infiltrated the roof and the apex of the orbit.
Clinical ophthalmological examination revealed papilloedema
and exophthalmos. PET/CT correctly ruled out systemic
metastasis.
PET/CT in secondary orbital tumours (n=14)
Whole-body PET/CT correctly assessed six patients with con-
tinuous tumour spread to the orbit and eight orbital metastases.
Histology-proven primary tumours of these patients included
breast cancer (n=3), prostate cancer (n=2), invasive follicular
thyroid carcinoma (n=1), cutaneous melanoma (n=1) and neu-
roendocrine carcinoma of the small intestine (n=1). While
(18F)-FDG accumulation indicates an elevated glucose metabol-
ism in general, (18F)-FEC and (68Ga)-DOTATATE were specif-
ically employed for suspected metastasis of prostate cancer and
neuroendocrine carcinoma, respectively. Further metastatic sites
in patients with orbital metastases included osseous (n=8),
hepatic (n=4), pulmonary (n=2) as well as one cutaneous, mus-
cular and endometrium metastasis, respectively.
Lymph node metastases were present in two of eight patients
with haematogenous tumour spread (25%) and in five of six
patients with continuous tumour spread (83%). Lymph node
involvement was more frequent in patients with local carcin-
omas extending into the orbit (Fisher’s exact test, p=0.05).
Further organ involvement was present in all eight patients suf-
fering from orbital metastases, whereas only one patient with
infiltrative carcinoma had further distant metastases (17%). This
was highly significant (Fisher’s exact test, p=0.003). These
results are summarised in table 2.
In metastatic patients, seven orbital metastases expressed an
elevated metabolism indicating vital tumour tissue and conse-
quently leading to treatment decision. In one patient, PET/CT
could exclude vital orbital tumour tissue after radiation therapy
(patient number 13, figure 2), yet further distant lymph node,
pulmonary as well as osseous metastases were present. The
patient then underwent chemotherapy.
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In patient 1 suffering from prostate cancer, previously unknown
local recurrence was detected by (18F)-FEC PET/CT (figure 3).
Thus, PET/CT had influence on treatment decision in all
patients.
DISCUSSION
Combined morphological and metabolic data in PET/CT
improve diagnostic accuracy. This plays an important role in the
selection of adequate therapy. Higher patient convenience,
saving of time and greater diagnostic confidence are important
advantages of combined imaging.16
PET/CT in the child presenting with an orbital mass
In spite of the radiation exposure, PET/CT with reduced dose
(110 MBq) was applied in one case of a primary orbital tumour.
The child was symptomatic and presented with apparent exoph-
thalmos and papilloedema implied neoplastic growth. For paediat-
ric rhabdomyosarcoma, PET/CT has already been proven superior
to conventional radiological evaluation in the detection of distant
metastases17 and lymph node metastases18 and was superior in
detecting objective response after chemotherapy compared with
conventional imaging methods (92% vs 84%).18 Whole-body
(18F)-FDG PET/CT may be useful in detecting metastases of
rhabdomyosarcoma that are not clinically evident and upstaging in
comparison with MRI staging (lymph node and osseous metasta-
ses) has been reported previously.19 PET/CT has thus been proven
a meaningful tool in the staging of carcinoma and rhabdomyosar-
coma.20 In the child with rhabdomyosarcoma in this study, PET/
CT was successfully employed for staging (exclusion of further
distant metastasis) and restaging after chemotherapy.
Figure 1 Classification of final diagnoses of orbital lesions included (n=15).









within the orbit Final diagnosis PET-Tracer Validation
Ocular
symptoms
1 M 68 CyberKnife OS Superiorly Metastasis (prostate cancer) (18F)-FEC MRI BCVA ↓
2 M 71 CyberKnife, hormone
therapy
OD Temporally Metastasis (prostate cancer) (18F)-FEC MRI None
3 F 62 CyberKnife,
chemotherapy
OS Inferiorly Metastasis (breast cancer) (18F)-FDG MRI, PET/CT None
4 F 46 Surgical resection,
radiation therapy
OD Medially Neuroendocrine carcinoma (18F)-FDG Histopathology VF defects
5 F 60 Surgical resection,
radiation therapy
OS Superiorly Metastasis (thyroid cancer) (18F)-FDG Histopathology Double vision
6 M 72 Radiation therapy,
DOTA therapy
OS Temporally Metastasis (neuroendocrine
carcinoma)
(68Ga)-DOTATATE MRI None
7 F 58 Radiation therapy,
hormone therapy
OD Medially Metastasis (breast cancer) (18F)-FDG MRI Enophthalmos
8 M 71 Surgical resection OD Medially Squamous cell carcinoma (18F)-FDG Histopathology Skin alteration
9 M 7 Chemotherapy OS Superiorly, orbital apex Rhabdomyosarcoma (18F)-FDG Histopathology Exophthalmos
10 M 70 Radiation therapy OD Medially Nasopharyngeal carcinoma (18F)-FDG Histopathology BCVA ↓
11 F 79 Surgical resection OS Superiorly, medially Meibomian gland carcinoma (18F)-FDG Histopathology Inflammation
12 M 76 Surgical resection OD Medially, lacrimal duct Squamous cell carcinoma (18F)-FDG Histopathology Skin alteration
13 F 76 Chemotherapy,
Radiotherapy
OS Superiorly Metastasis (breast cancer) (18F)-FDG Histopathology Ptosis
14 M 68 Chemotherapy OD
OS
Medially Neuroendocrine carcinoma (18F)-FDG Histopathology Double vision
15 F 76 Radiation therapy,
immunotherapy
OS Orbital apex Metastasis (cutaneous
melanoma)
(18F)-FDG Histopathology BCVA ↓
BCVA, ↓, Decrease in best-corrected visual acuity; FDG, fluorodeoxyglucose; FEC, fluoroethylcholine; OD, Right eye; OS, Left eye; PET, positron emission tomography; Pt., patient; VF,
Visual field.
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PET/CT for detection of lymph node metastases
in orbital tumours
We employed PET/CT for diagnosing metastasis to the orbit
and for detecting the extent of lymph node involvement from
invasive malignancies. This has been widely evaluated for the
head and neck region in cervical carcinoma of unknown
primary.21 PET/CT has the potential to improve the manage-
ment of patients with carcinoma in the sinus/nasal area and
orbit.2 Variable diagnostic accuracy has been shown for
(18F)-FDG PET in the detection of different histological
tumour entities.22
Lymph node staging has extensive consequences for the
patients ranging from no adjuvant therapy to very radical
therapy like neck dissection, brachytherapy or chemotherapy in
advanced tumours. Advantages of lymph node evaluation via
PET/CT versus sentinel lymph node biopsy are of interest for
the tumours included in our study that extended into the orbit.
PET/CT is less invasive than biopsy enabling whole-body evalu-
ation within the same examination. Furthermore, indication for
sentinel lymph node biopsy in conjunctival and eyelid tumours
is limited to specific tumour stages, according to a recent review,
and multi-institutional controlled trials are warranted.23 Data on
sentinel lymph node biopsy on tumours extending into the orbit
are even more limited. A comparative study on the sensitivity
and specificity of sentinel lymph node biopsy and lymph node
staging via PET/CT would be of great value. Additional lymph
node metastases may modify treatment decision (neck dissection
or delineation of the radiation treatment field).
Field-of-view in PET/CT
In clinical practice in both nuclear medicine and radiology,
increasing spatial resolution of images is achieved by decreasing
the field-of-view, because the whole reconstruction matrix is used
for a smaller anatomical region. Consequently, this reduces pixel
size within the images. The field-of-view reflects the maximum
diameter of the reconstructed digital image. Its value can be
selected by the radiologist depending on the dimensions of the
anatomical region of interest. The choice of a small field-of-view
allows increased spatial resolution within the image, because the
whole reconstruction matrix is used for a smaller region. A large
field-of-view is usually selected for whole-body-PET/CT imaging
to fully include even the widest axial dimensions of the human
body, that is, the shoulders and the hips, in search of distant
metastasis. In this study, as orbital metastases were associated
with further distant metastases in all cases, a large field-of-view in
PET/CT was reasonable in order not to overlook any distant
metastasis. However, detailed imaging of the head and neck
region was of utmost importance in lesions extending into the
orbit. These infiltrative tumours were more likely to develop
lymph node metastases rather than distant metastases. Therefore,
additional image reconstructions with a small field-of-view were
chosen to cover the head and neck regions in these patients with
high spatial resolution. Whenever imaging raw data are kept
available, the field-of-view can be changed in retrospect.
PET/CT in orbital metastases
The actual incidence of metastases to the eye and orbit is diffi-
cult to quantify, as patients may remain asymptomatic and
succumb to their primary cancer before clinical detection of the
ocular metastasis. Yet, with improvements in systemic therapy
and oncological management, patients suffering from metastatic
cancer survive longer and, therefore, orbital metastases may
manifest more frequently.24
Of course, clinical examination remains the first important
method for evaluation of orbital symptoms. However, for
biopsy planning, CT is necessary for assessment of bony inva-
sion or if the tumour is localised in the orbital apex, making
ultrasound examination difficult.
Whole-body PET/CT imaging can be employed for detecting
primary site in metastatic disease and defining the total extent
of disseminated disease. PET/CT can indicate vital tumour
metabolism, and selectively binding radiopharmaceutical tracers,
which were applied for diagnostics of prostate cancer or neu-
roendocrine tumour metastases in this study, can determine the
origin of tumour cells. PET may overcome CT limitations by its
ability to visualise vital tumour tissue by increased FDG uptake
and therefore identify residual cancer or recurrence.2 In this
study, recurrence of prostate cancer was detected on (18F)-FEC
PET/CT in one patient, thus modifying treatment. In a large
retrospective study evaluating different non-typical sites of
metastasis of neuroendocrine tumours, the most common loca-
tions were cardiac and breast metastases followed by retro-
orbital metastases.25 In cases with known neuroendocrine
tumours, (68Ga)-DOTATATE PET/CT can delineate the orbital
mass in question and can determine tumour biology in terms of
SSRT expression. In the present study, a previously unknown
orbital metastasis could be diagnosed correctly as such with
(68Ga)-DOTATATE PET/CT.
In PET/CT, detection of distant metastases may be performed
within the same whole-body scan. This has been reported in
Table 2 Tumour spread in adults with orbital metastases vs











Bony infiltration 5 (63%) 5 (83%) n.s.
Lymph node metastases 2 (25%) 5 (83%) 0.05
Further distant metastases 8 (100%) 1 (17%) 0.003
n.s., not significant.
Figure 2 Intraorbital breast cancer metastasis invading the levator
complex demonstrating low fluorodeoxyglucose uptake after radiation
therapy (patient 13). The CT scan on the left shows the orbital
metastasis before (within the red frame) and after radiotherapy. The
scan on the right is taken from the same examination after therapy but
is showing combined positron emission tomography/CT imaging.
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27% of patients by Wild et al2 for carcinomas of the sinus/nasal
area and orbit.2 The group reported superior performance of
PET/CT for restaging locoregional carcinoma of the sinus, nasal
area and orbit, but not for initial staging.
We found additional systemic metastases present in all eight
patients who presented with orbital metastases (100%) within
this study. Orbital metastases usually spread hematogenously.6
Disseminated disease was significantly more frequent in patients
with haematogenous orbital metastases than in patients with infil-
trative tumour growth (p=0.003). We therefore conclude that
whole-body PET/CT including imaging of the head and orbit
should be employed in patients with systemic metastases present-
ing with recent orbital symptoms. Additionally, PET/CT should
be performed in patients with tumour history without known
metastasis and orbital symptoms as these symptoms can be the
first manifestation of diffuse systemic metastases. PET/CT seems
most appropriate for advanced cancers of the orbit, eyelid and
eye with high risk of distant metastasis.15
CONCLUSION
By employing PET/CT, both tumour morphology and cell
metabolism can be assessed in one single examination, thereby
helping in overcoming the limitations of each modality used
separately. As orbital metastases did not present as solitary find-
ings in the present study, whole-body staging is of great value
for the evaluation of metastatic spread and specific radiophar-
maceutical tracers can be employed for this purpose. For infil-
trating tumours associated with lymph node metastases, PET/
CT has proven valuable for the evaluation of lymph node
involvement. Additionally, PET/CT can be of importance in par-
ticular settings of paediatric ocular diagnostics.
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